1 Zhang LL,Sun LH.Impacts of dagnosis-related groups payment on the healthcare providers′ behavior in China:a cross-sectional study among physicians[J].Risk manag Healthc Policy,2021,14:2263-2276. 2 王晖,张国俊,于发斌,等.DRG付费的潜在风险及应对策略[J].卫生经济研究,2020,37(7):3. 3 栗景坤,李习,刘美娜.基于评价指标的非小细胞肺癌治疗质量影响因素分析[J].中国医院统计,2018,25(6):5. 4 翟雨,刘乃鹏.基于DRGs的支气管肺癌临床路径实施效果分析[J].淮海医药,2023,41(3):277-279. 5 夏景林,李敏奇,陈英耀,等.公立医院临床医师临床路径应用状况分析[J].中国医院管理,2017,37(7):5-8. 6 陈香.基于DRG付费方式的公立医院成本管理分析[J].投资与合作,2024,(6):187-189. 7 吴妮,周晓媛,王寓凡.DRG付费下康复患者住院费用和住院天数的影响因素研究——基于双反应变量多水平模型[J].卫生经济研究,2024,41(6):72-77. 8 Aragón MJ,Chalkley M,Kreif N.The long-run effects of diagnosis related group payment on hospital lengths of stay in a publicly funded health care system:evidence from 15 years of micro data[J].Health Econ.2022,31(6):956-972. 9 Lin KH,Li YF,Yao YF,et al.The impact of an innovative payment method on medical expenditure,efficiency,and quality for inpatients with different types of medical insurance:evidence from a pilot city,China[J].Int J Equity Health,2024,23(1):115. 10 Chang WF,Yan XY,Ling H,et al.A study of the types and manifestations of physicians′ unintended behaviors in the DRG payment system[J].Front Public Health,2023,11:1141981. 11 Chao YC,Zhou JB,HSU SJ,et al.Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer[J].Transl Lung Cancer Res,2022,11(2):295-306. 12 Takayama Y,Nakamura T,Fukushiro Y,et al.Coexistence of emphysema with non-small-cell lung cancer predicts the therapeutic efficacy of immune checkpoint inhibitors[J].In vivo(Athens,Greece),2021,35(1):467-474. 13 Caramori G,Ruggeri P,Mumby S,et al.Molecular links between COPD and lung cancer:new targets for drug discovery?[J].Expert Opinion Ther Targets,2019,23(6):539-553. 14 周美多.临床护理路径在老年晚期非小细胞肺癌患者中的应用[J].中国民康医学,2019,31(17):168-170. |